Literature DB >> 17715056

Crystal structure of the incretin-bound extracellular domain of a G protein-coupled receptor.

Christoph Parthier1, Martin Kleinschmidt, Piotr Neumann, Rainer Rudolph, Susanne Manhart, Dagmar Schlenzig, Jörg Fanghänel, Jens-Ulrich Rahfeld, Hans-Ulrich Demuth, Milton T Stubbs.   

Abstract

Incretins, endogenous polypeptide hormones released in response to food intake, potentiate insulin secretion from pancreatic beta cells after oral glucose ingestion (the incretin effect). This response is signaled by the two peptide hormones glucose-dependent insulinotropic polypeptide (GIP) (also known as gastric inhibitory polypeptide) and glucagon-like peptide 1 through binding and activation of their cognate class 2 G protein-coupled receptors (GPCRs). Because the incretin effect is lost or significantly reduced in patients with type 2 diabetes mellitus, glucagon-like peptide 1 and GIP have attracted considerable attention for their potential in antidiabetic therapy. A paucity of structural information precludes a detailed understanding of the processes of hormone binding and receptor activation, hampering efforts to develop novel pharmaceuticals. Here we report the crystal structure of the complex of human GIP receptor extracellular domain (ECD) with its agonist, the incretin GIP(1-42). The hormone binds in an alpha-helical conformation in a surface groove of the ECD largely through hydrophobic interactions. The N-terminal ligand residues would remain free to interact with other parts of the receptor. Thermodynamic data suggest that binding is concomitant with structural organization of the hormone, resulting in a complex mode of receptor-ligand recognition. The presentation of a well structured, alpha-helical ligand by the ECD is expected to be conserved among other hormone receptors of this class.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17715056      PMCID: PMC1955799          DOI: 10.1073/pnas.0706404104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  51 in total

1.  Crystal structure of human parathyroid hormone 1-34 at 0.9-A resolution.

Authors:  L Jin; S L Briggs; S Chandrasekhar; N Y Chirgadze; D K Clawson; R W Schevitz; D L Smiley; A H Tashjian; F Zhang
Journal:  J Biol Chem       Date:  2000-09-01       Impact factor: 5.157

2.  Crystal structure of the ectodomain of Methuselah, a Drosophila G protein-coupled receptor associated with extended lifespan.

Authors:  A P West; L L Llamas; P M Snow; S Benzer; P J Bjorkman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

3.  Substructure solution with SHELXD.

Authors:  Thomas R Schneider; George M Sheldrick
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2002-09-28

4.  Glucose-dependent insulinotropic polypeptide (GIP): development of DP IV-resistant analogues with therapeutic potential.

Authors:  Simon A Hinke; Francis Lynn; Jan Ehses; Nathalie Pamir; Susanne Manhart; Kerstin Kühn-Wache; Fred Rosche; Hans-Ulrich Demuth; Raymond A Pederson; Christopher H S McIntosh
Journal:  Adv Exp Med Biol       Date:  2003       Impact factor: 2.622

5.  Full activation of chimeric receptors by hybrids between parathyroid hormone and calcitonin. Evidence for a common pattern of ligand-receptor interaction.

Authors:  C Bergwitz; T J Gardella; M R Flannery; J T Potts; H M Kronenberg; S R Goldring; H Jüppner
Journal:  J Biol Chem       Date:  1996-10-25       Impact factor: 5.157

6.  Localization of the domains involved in ligand binding and activation of the glucose-dependent insulinotropic polypeptide receptor.

Authors:  R W Gelling; M B Wheeler; J Xue; S Gyomorey; C Nian; R A Pederson; C H McIntosh
Journal:  Endocrinology       Date:  1997-06       Impact factor: 4.736

Review 7.  Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes.

Authors:  Michael A Nauck; Birgit Baller; Juris J Meier
Journal:  Diabetes       Date:  2004-12       Impact factor: 9.461

8.  Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.

Authors:  T J Kieffer; C H McIntosh; R A Pederson
Journal:  Endocrinology       Date:  1995-08       Impact factor: 4.736

9.  Inhibition of gastric inhibitory polypeptide signaling prevents obesity.

Authors:  Kazumasa Miyawaki; Yuichiro Yamada; Nobuhiro Ban; Yu Ihara; Katsushi Tsukiyama; Heying Zhou; Shimpei Fujimoto; Akira Oku; Kinsuke Tsuda; Shinya Toyokuni; Hiroshi Hiai; Wataru Mizunoya; Tohru Fushiki; Jens Juul Holst; Mitsuhiro Makino; Akira Tashita; Yukari Kobara; Yoshiharu Tsubamoto; Takayoshi Jinnouchi; Takahito Jomori; Yutaka Seino
Journal:  Nat Med       Date:  2002-06-17       Impact factor: 53.440

Review 10.  Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes.

Authors:  Victor A Gault; Peter R Flatt; Finbarr P M O'Harte
Journal:  Biochem Biophys Res Commun       Date:  2003-08-22       Impact factor: 3.575

View more
  97 in total

1.  Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) has a critical role in GLP-1 peptide binding and receptor activation.

Authors:  Cassandra Koole; Denise Wootten; John Simms; Laurence J Miller; Arthur Christopoulos; Patrick M Sexton
Journal:  J Biol Chem       Date:  2011-12-06       Impact factor: 5.157

Review 2.  Structure and mechanism for recognition of peptide hormones by Class B G-protein-coupled receptors.

Authors:  Kuntal Pal; Karsten Melcher; H Eric Xu
Journal:  Acta Pharmacol Sin       Date:  2012-01-23       Impact factor: 6.150

3.  Secretin family (Class B) G protein-coupled receptors - from molecular to clinical perspectives.

Authors:  David R Poyner; Debbie L Hay
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 4.  The significance of G protein-coupled receptor crystallography for drug discovery.

Authors:  John A Salon; David T Lodowski; Krzysztof Palczewski
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

5.  Mutational and cysteine scanning analysis of the glucagon receptor N-terminal domain.

Authors:  Martine Prévost; Pascale Vertongen; Vincent Raussens; David Jonathan Roberts; Johnny Cnudde; Jason Perret; Magali Waelbroeck
Journal:  J Biol Chem       Date:  2010-07-20       Impact factor: 5.157

Review 6.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

7.  The major determinant of exendin-4/glucagon-like peptide 1 differential affinity at the rat glucagon-like peptide 1 receptor N-terminal domain is a hydrogen bond from SER-32 of exendin-4.

Authors:  R J Mann; N E Nasr; J K Sinfield; E Paci; D Donnelly
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

Review 8.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

9.  Dimeric arrangement of the parathyroid hormone receptor and a structural mechanism for ligand-induced dissociation.

Authors:  Augen A Pioszak; Kaleeckal G Harikumar; Naomi R Parker; Laurence J Miller; H Eric Xu
Journal:  J Biol Chem       Date:  2010-02-19       Impact factor: 5.157

10.  The predicted binding site and dynamics of peptide inhibitors to the Methuselah GPCR from Drosophila melanogaster.

Authors:  Jiyoung Heo; William W Ja; Seymour Benzer; William A Goddard
Journal:  Biochemistry       Date:  2008-12-02       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.